lncRNA NEAT1在急性髓系白血病患者外周血中的表达及其与预后的关系-现代医学

lncRNA NEAT1在急性髓系白血病患者外周血中的表达及其与预后的关系

单位：四川大学华西医院血液内科, 四川成都 610000

分类号：R733.71

出版年·卷·期（页码）：2020·39·第五期（573-578）

摘要：

目的：探究长链非编码RNA NEAT1（lncRNA NEAT1）在急性髓系白血病（AML）患者外周血中的表达，分析其与临床预后的关系。方法：选择2011年3月至2014年3月本院收治的AML患者76例（AML组）和来本院体检的健康人32例（对照组）作为研究对象，采集各个研究对象的外周血液标本，采用实时荧光定量PCR（qRT-PCR）法检测外周血单个核细胞中lncRNA NEAT1的表达；分析lncRNA NEAT1表达与AML患者临床病理特征的关系；对出院后AML患者进行随访，分析lncRNA NEAT1表达与AML患者预后的关系。结果：lncRNA NEAT1在AML患者外周血单个核细胞中表达明显高于对照组（P<0.05）；lncRNA NEAT1在AML患者外周血单个核细胞中的表达与患者的年龄、性别、FAB亚型无关（P>0.05），与危险度分层、白细胞（WBC）含量、血红蛋白（Hb）含量及血小板（PLT）含量有关（P<0.05）；lncRNA NEAT1高表达组AML患者5年生存率为32.50%，显著低于低表达组的55.56%（P<0.05）；多因素分析显示，lncRNA NEAT1表达和危险度分层是影响AML患者预后的独立危险因素（HR=2.513，95% CI 1.327~4.759；HR=2.781，95% CI 1.753~4.412，均P<0.05）。结论：lncRNA NEAT1在AML患者外周血单个核细胞中高表达，其表达变化可以反映AML的发生、发展进程，可能作为AML预后判断的一个重要参考指标。

Objective: To investigate the expression of long non-coding small RNA NEAT1 (lncRNA NEAT1) in peripheral blood of acute myeloid leukemia (AML) and to analyze its relationship with clinical prognosis. Methods: 76 AML patients (AML group) admitted to our hospital and 32 healthy persons (control group) who came to our hospital for physical examination from March 2011 to March 2014 were collected as the research objects. Peripheral blood samples were collected from all subjects, the expression of lncRNA NEAT1 in peripheral blood mononuclear cells was detected by real-time fluorescence quantitative PCR (qRT-PCR); the relationship between NEAT1 expression with clinicopathological features of AML patients was analyzed; after discharge, AML patients were followed-up, the relationship between the expression of lncRNA NEAT1 with the prognosis of AML patients was analyzed.Results: The expression of lncRNA NEAT1 in peripheral blood mononuclear cells of AML patients was significantly higher than that of control group (P<0.05); the expression of lncRNA NEAT1 in peripheral blood mononuclear cells of AML patients was not related to age, sex and FAB subtype (P> 0.05), but related to risk stratification, white blood cell (WBC) content, hemoglobin(Hb) content and platelet(PLT) content (P< 0.05); the 5-year survival rate of patients with AML in the lncRNA NEAT1 high expression group was 32.50%, which was significantly lower than 55.56% in the low expression group (P<0.05). Multivariate analysis showed that the expression of lncRNA NEAT1 and risk stratification were independent risk factors affecting the prognosis of AML patients (HR=2.513, 95% CI 1.327-4.759; HR=2.781, 95% CI 1.753-4.412, all P<0.05). Conclusion: LncRNA NEAT1 is highly expressed in peripheral blood mononuclear cells of AML patients, and its expression change can reflect the occurrence and development of AML, which may be an important prognostic indicator for AML.

参考文献：

[1] ADES L, PREBET T, STAMATOULLAS A, et al. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase Ⅱ study by the Groupe Francophone Des Myelodysplasies[J].Haematologica, 2017,102(4):728-735.
[2] 韩娜, 丰明星, 赵伟伟, 等.微移植治疗老年急性髓性白血病疗效及患者生活质量随访[J].现代医学, 2015, 43(3):288-290.
[3] CAO J, ZHANG Y, YANG J, et al. NEAT1 regulates pancreatic cancer cell growth, invasion and migration though mircroRNA-335-5p/c-met axis[J].Am J Cancer Res,2016,6(10):2361-2374.
[4] 中华医学会血液学分会. 急性髓系白血病(复发难治性)中国诊疗指南(2011年版)[J].中华血液学杂志, 2011,32(12):887-888.
[5] SABATTINI E, BACCI F, SAGRAMOSO C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica, 2010,102(3):83-87.
[6] LIU W, LIU J, SONG Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017:an observational study[J].J Hematol Oncol, 2019,12(1):22-32.
[7] BEST-AGUILERA C, RODRIGO G O, ELIZABETH G A, et al. Treatment of acute myeloid leukemia with the FLT3 gene mutation[J].Curr Oncol Rep, 2017,19(3):21-33.
[8] 陈月, 王春玲, 于亮, 等.具有合并症的急性髓系白血病老年患者的临床特征及预后分析[J].东南大学学报(医学版), 2019, 38(4):618-623.
[9] CHEN Z H, WANG W T, HUANG W, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway[J].Cell Death Differ, 2017,24(2):212-224.
[10] 贾振薇, 李焱, 崔桂荣, 等.LncRNA KCNQ1OT1在急性髓系白血病患者中的表达及其临床意义[J].中国实验血液学杂志, 2018,26(3):653-657.
[11] 郑转珍, 贡荣, 李国霞, 等.长链非编码RNA HOTAIR在急性髓系白血病患者外周血中的表达变化及意义[J].山东医药, 2018,58(5):25-28.
[12] 辛文秀, 郑小卫, 李清林, 等.长链非编码RNA NEAT1在肿瘤中的功能和作用机制研究进展[J].中国现代应用药学, 2018,35(10):1580-1585.
[13] DING N, WU H, TAO T, et al. NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2[J].Onco Targets Ther, 2017,10(1):4905-4915.
[14] FANG J, QIAO F, TU J, et al. High expression of long non-coding RNA NEAT1 indicates poor prognosis of human cancer[J].Oncotarget, 2017,8(28):45918-45927.
[15] ZENG C, XU Y, XU L, et al. Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells[J].BMC Cancer, 2014,14:693.
[16] GAO C, ZHANG J, WANG Q, et al. Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia[J].Oncol Lett, 2016,12(2):1051-1057.
[17] ZHAO C, WANG S, ZHAO Y, et al. Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia[J].J Cell Physiol, 2019, 234(5):6161-6172.
[18] 陈立刚, 刘永华. 急性髓系白血病患者不同阶段外周血髓系抑制细胞的表达特征分析[J].医学研究生学报, 2016,29(6):629-632.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录